cerca CERCA
Lunedì 21 Giugno 2021
Aggiornato: 09:50
Temi caldi

treatment

European Hematology Association - Daratumumab Maintenance Improves Progression-Free Survival After Autologous Stem Cell Transplantation in Multiple Myeloma Patients

THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ -- Part 1 of the CASSIOPEIA phase-3 study compared the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (D-VTd) induction/consolidation with VTd alone in transplant-eligible patients with newly diagnosed multiple myeloma. The results of the study showed superior efficacy of D-VTd over VTd alone in combination with autologous stem cell transplantation (ASCT), which led to the regulatory approval of the treatment. Here, we pres...

European Hematology Association - Pegcetacoplan Maintains a Durable Response in Patients with Paroxysmal Nocturnal Hemoglobinuria Through Week 48

THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ -- The PEGASUS phase-3 study previously demonstrated that pegcetacoplan, a drug controlling intra- and extravascular hemolysis, was superior to eculizumab in patients with paroxysmal nocturnal hemoglobinuria at the week 16 endpoint of the randomized controlled period (RCP). After week 16, patients entered an open-label period where all patients were placed on pegcetacoplan treatment. Here, we show the efficacy and safety of pegcetacoplan in 77 pa...

European Hematology Association - Genetic Modification of Autologous Hematopoietic Stem Cells: A Potential Treatment for Mucopolysaccharidosis Type I Hurler

THE HAGUE, Netherlands, June 11, 2021 /PRNewswire/ -- Mucopolysaccharidosis type I Hurler (MPS-IH) is caused by a deficiency in alpha-L-iduronidase (IDUA) and is typically managed by allogeneic hematopoietic stem cell (HSC) transplantation, which has shown high rates of success when patients are treated at a young age. However, skeletal abnormalities remain and progressive neurocognitive deterioration over time severely affect a patient's quality of life. In this first-in-human phase I/II clinica...

CGTN: Peng Liyuan calls for global efforts in AIDS and TB prevention and treatment

BEIJING, June 8, 2021 /PRNewswire/ -- Peng Liyuan, wife of Chinese President Xi Jinping, called on people from all walks of life in all countries to join hands and take action to strengthen the prevention and treatment of AIDS and tuberculosis (TB), in order to benefit all mankind and build a global community of health for all.

Xinhua Silk Road: China's WELLE Group expects new development in wet garbage treatment

BEIJING, April 27, 2021 /PRNewswire/ -- As more efforts are being made on waste sorting in China, WELLE Group, one of China's leading enterprises in the field of wet garbage treatment, has achieved an outstanding sales performance in 2020 with revenue up 17.29 percent year on year and cash flow from operating activities exceeding 363 million yuan.

alternate text

Save Alexei Navalny's life Di Maio tells Russia

Italy's foreign minister Luigi Di Maio on Monday urged Russian authorities to give jailed Kremlin critic Alexei Navalny critical medical care without delay, the foreign ministry said in a statement

Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)

TORONTO, March 11, 2021 /PRNewswire/ -- Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and...

Femtech startup OCON Healthcare announces last patient in phase IIa clinical study, evaluating its intrauterine drug delivery platform IUB™ SEAD™, a non-invasive treatment for abnormal uterine bleeding (AUB)

The trial assesses the safety and efficacy of the IUB™ SEAD™, a disruptive treatment for AUB. In this study, 50% of the participating patients have reached the End of the Study point, demonstrating a significant reduction in bleeding, avoiding the need to undergo invasive uterine ablation procedures or even a hysterectomy

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to ...

Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs

SEOUL, South Korea, Jan. 18, 2021 /PRNewswire/ -- Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.

TricValve® Transcatheter Bicaval Valves System granted Designation as Breakthrough Device by the U.S. Food and Drug Administration (FDA)

VIENNA, Dec. 22, 2020 /PRNewswire/ -- P+F Products + Features GmbH has been granted designation as a Breakthrough Device for the company's lead product, the TricValve® Transcatheter Bicval Valves System by the U.S. Food & Drug Administration on December 15th 2020. The TricValve® is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. "The TricValve® system represents a new technology offering a  pote...

The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention

GENEVA and CASTRES , France, Dec. 14, 2020 /PRNewswire/ -- The EspeRare Foundation and the Pierre Fabre group announced today that they have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare, debilitating congenital disease. The next clinical study is expected to start in 2021 and will aim at qualifying and registering what may become the first appr...

ora in
Prima pagina
articoli
in Evidenza